今年来、近3年、近5年均居上游！九坤、幻方、明汯、国源信达、陈宇旗下产品做到了！

Core Viewpoint - The article emphasizes the performance of private equity funds in China's capital market, highlighting the challenges of maintaining top rankings over different time frames amidst market volatility [1]. Group 1: Subjective Long/Short Strategies - A total of 23 private equity products have ranked in the top 20% for short-term (January to August), medium-term (three years), and long-term (five years) performance [1]. - As of August 2025, there are 1,974 subjective long/short private equity products reported for this year, 1,353 for the last three years, and 760 for the last five years [1]. Group 2: Quantitative Long/Short Strategies - 21 products from quantitative long/short strategies have also ranked in the top 50% across all three performance periods [5]. - Among these, 11 products belong to large-scale quantitative private equity firms, indicating a strong presence in the market [5]. Group 3: Futures and Derivatives Strategies - 19 private equity products have achieved top 30% performance across short, medium, and long-term periods in the futures and derivatives category [8]. - As of August 2025, there are 678 products reported for this year, 403 for the last three years, and 162 for the last five years in this strategy [8]. Group 4: Multi-Asset Strategies - 18 multi-asset strategy products have ranked in the top 30% for all three performance periods [12]. - The article notes that large-scale private equity firms like Blackwing Asset and Duration Investment have products listed among the top performers [12]. Group 5: Market Outlook - The market is expected to experience fluctuations, with technology, pharmaceuticals, and new consumption identified as key investment areas for the next decade [4]. - The article mentions that the A-share market is likely to remain in a bullish phase, with significant opportunities in sectors like technology and healthcare [4].